449 Spam-Free Article(s) Found
Sort:
Date
Filter:
All
Symbol Name Last Close Mkt Cap DailyStocks'
Rating
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Tuesday’s Close
SNY Sanofi $43.75 $109.14B N/A
Article Searches
What's in the Cards for Novavax (NVAX) This Earnings Season? http://www.zacks.com/stock/news/357628/whats-in-the-cards-for-novavax-nvax-this-earnings-season?cid=CS-ZC-FT-357628 Mar 04, 2019 - Novavax (NVAX) is expected to provide updates on its lead vaccine candidate, Resvax when it reports fourth-quarter 2018 results.
Regeneron-Sanofi Get CHMP Nod for Dupixent Label Expansion http://www.zacks.com/stock/news/357622/regeneron-sanofi-get-chmp-nod-for-dupixent-label-expansion?cid=CS-ZC-FT-357622 Mar 04, 2019 - The CHMP gives a positive opinion for the label expansion of Regeneron (REGN) and Sanofi's Dupixent for the treatment of asthma in Europe.
Big Pharma's Showdown With Congress Over Drug Pricing: What It Really Means for You https://www.fool.com/investing/2019/02/27/big-pharmas-showdown-with-congress-over-drug-prici.aspx?source=iedfolrf0000001 Feb 27, 2019 - A Senate committee roasted top executives of the biggest drugmakers. But will anything change for ordinary Americans?
Congress Grills Drugmakers: 5 Key Takeaways https://www.fool.com/investing/2019/02/26/congress-grills-drugmakers-5-key-takeaways.aspx?source=iedfolrf0000001 Feb 26, 2019 - Top drug companies addressed sky-high drug prices on Capitol Hill today.
2 More Gene Therapy Stocks on Big Pharma's Buyout Radar https://www.fool.com/investing/2019/02/26/2-more-gene-therapy-stocks-on-big-pharmas-buyout-r.aspx?source=iedfolrf0000001 Feb 26, 2019 - Roche's big step into the gene-editing space will spark interest for these two stocks.
Ascendis Pharma Files IND for Hypoparathyroidism Candidate http://www.zacks.com/stock/news/354249/ascendis-pharma-files-ind-for-hypoparathyroidism-candidate?cid=CS-ZC-FT-354249 Feb 13, 2019 - Ascendis Pharma (ASND) submits regulatory application to initiate a phase II study in the United States on its hypoparathyroidism therapy candidate, TransCon PTH.
Pharma Stock Roundup: Q4 Earnings at MRK, LLY, CHMP Nod for Several Drugs http://www.zacks.com/stock/news/353203/pharma-stock-roundup-q4-earnings-at-mrk-lly-chmp-nod-for-several-drugs?cid=CS-ZC-FT-353203 Feb 08, 2019 - Merck (MRK) and Lilly (LLY) report Q4 results. CHMP gives nod to several drugs.
Alnylam's (ALNY) Q4 Earnings and Revenues Beat Estimates http://www.zacks.com/stock/news/353200/alnylams-alny-q4-earnings-and-revenues-beat-estimates?cid=CS-ZC-FT-353200 Feb 08, 2019 - Alnylam (ALNY) incurs wider year-over-year loss in the fourth quarter of 2018.
Sanofi (SNY) CEO Olivier Brandicourt on Q4 2018 Results - Earnings Call Transcript https://seekingalpha.com/article/4239163-sanofi-sny-ceo-olivier-brandicourt-q4-2018-results-earnings-call-transcript?source=feed_sector_healthcare Feb 07, 2019 -
Sanofi (SNY) Q4 Earnings Top, Genzyme Unit Drives Sales Growth http://www.zacks.com/stock/news/352788/sanofi-sny-q4-earnings-top-genzyme-unit-drives-sales-growth?cid=CS-ZC-FT-352788 Feb 07, 2019 - Sanofi (SNY) beat estimates for earnings and missed the same for sales in the fourth quarter. The Specialty Care unit drove top-line growth.

Pages: 12345678910...45

<<<Page 5>